Real-World look at gut drug for colitis patients
NCT ID NCT05069259
Summary
This study observed how well the approved drug tofacitinib worked for adults in Switzerland with moderate to severe ulcerative colitis. It aimed to gather real-world data on symptom control and gut inflammation by having patients complete questionnaires and use a home stool test. The study was terminated early after enrolling 18 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Fribourgeois de Gastroenterologie
Fribourg, Switzerland
-
Clarunis, Universitätsspital
Basel, Switzerland
-
Kantonsspital Baselland
Liestal, Switzerland
-
Kantonsspital St, Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Verein IBD Study Group
Bern, CH - 3012, Switzerland
Conditions
Explore the condition pages connected to this study.